Current Problems in Cardiology
Volume 33, Issue 4 , Pages 163-196 , April 2008

The Diagnosis and Management of Cardiovascular Disease in Cancer Patients

References 

  1. Hoyert DL, Heron MP, Murphy SL, et al. Deaths: final data for 2003. Natl Vital Stat Rep. 2006;54:1–120
  2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442
  3. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900–2902
  4. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908–916
  5. Ewer MS, Ali MK, Mackay B, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol. 1984;2:112–117
  6. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–7826
  7. van Royen N, Jaffe CC, Krumholz HM, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol. 1996;77:843–850
  8. Tjeerdsma G, Meinardi MT, van Der Graaf WT, et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart. 1999;81:419–423
  9. Morandi P, Ruffini PA, Benvenuto GM, et al. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide. Bone Marrow Transplant. 2001;28:277–282
  10. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202–209
  11. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J. 1998;136:362–363
  12. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 2000;104:158–163
  13. Nousiainen T, Vanninen E, Jantunen E, et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med. 2002;251:228–234
  14. Urbanova D, Urban L, Carter A, et al. Cardiac troponins-biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma. 2006;53:183–190
  15. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749–2754
  16. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517–522
  17. Burjonroppa SCTA, Xiao LC, Johnson MM, et al. Cancer patients with markedly elevated B-type Natriuretic peptide may not have volume overload. Am J Clini Oncol. 2007;30:287–293
  18. Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med. 2006;57:485–498
  19. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122–3131
  20. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717
  21. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561–578
  22. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001;28:13–19
  23. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47–58
  24. Friedman MA, Bozdech MJ, Billingham ME, et al. Doxorubicin cardiotoxicity (Serial endomyocardial biopsies and systolic time intervals). JAMA. 1978;240:1603–1606
  25. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Exp Opin Drug Saf. 2006;5:791–809
  26. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–1084
  27. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258–2262
  28. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24
  29. Bristol-Myers Squibb Company: Sprycel (Dasatinib) prescribing information. Princeton, NJ, 2006.
  30. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;Jan 17 (Epub ahead print)
  31. Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol. 2001;28:20–27
  32. Ewer MS, Perez EA, Baselga J, et al. Cardiac Safety Guidelines for the adjuvant use of trastuzumab (Herceptin) in HER-2 positive breast cancer (St.Gallen Primary Therapy of Early Breast Cancer). In: St. Gallen, Switzlerland: 10th International Conference; 2007;p. 14–17March
  33. Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant. 1993;12:169–172
  34. Biganzoli L, Piccart MJ. The bigger the better? (or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer). Ann Oncol. 1997;8:1177–1182
  35. Nieto Y, Cagnoni PJ, Bearman SI, et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant. 2000;6:198–203
  36. Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118:31–36
  37. Klastersky J. Side effects of ifosfamide. Oncology. 2003;65(suppl 2):7–10
  38. Kandylis K, Vassilomanolakis M, Tsoussis S, et al. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol. 1989;24:395–396
  39. Schimmel KJ, Richel DJ, van den Brink RB, et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004;30:181–191
  40. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18:1725–1732
  41. Togna GI, Togna AR, Franconi M, et al. Cisplatin triggers platelet activation. Thromb Res. 2000;99:503–509
  42. Verweij J, Funke-Kupper AJ, Teule GJ, et al. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother. 1988;5:159–163
  43. Shao Y, Pardini L, Pardini RS. Enhancement of the antineoplastic effect of mitomycin C by dietary fat. Cancer Res. 1994;54:6452–6457
  44. Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol. 1990;1:409–414
  45. Kuropkat C, Griem K, Clark J, et al. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol. 1999;22:466–470
  46. Schober C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer. 1993;72:2242–2247
  47. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995;13:180–190
  48. Seidman AD, Reichman BS, Crown JP, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol. 1995;13:1152–1159
  49. Dombernowsky P, Gehl J, Boesgaard M, et al. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol. 1996;23:23–27
  50. Markman M, Kennedy A, Webster K, et al. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors. J Clin Oncol. 1998;16:3483–3485
  51. Dillman RO. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest. 2001;19:833–841
  52. Oshima K, Sakata-Yanagimoto M, Asano-Mori Y, et al. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplant. 2005;36:821–824
  53. Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood. 2004;104:655–658
  54. Basquiera AL, Berretta AR, Garcia JJ, et al. Coronary ischemia related to alemtuzumab therapy. Ann Oncol. 2004;15:539–540
  55. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779–1802
  56. D’Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005;23:7135–7142
  57. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med. 1988;85:549–551
  58. Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by interferon. BMJ. 1990;300:1174–1175
  59. Deyton LR, Walker RE, Kovacs JA, et al. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi’s sarcoma. N Engl J Med. 1989;321:1246–1249
  60. Zimmerman S, Adkins D, Graham M, et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother. 1994;9:291–299
  61. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699–709
  62. Tallaj JA, Franco V, Rayburn BK, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24:2196–2201
  63. Giesler G, Lenihan D, Tong A, et al. Withdrawal of ace-inhibitors and beta blockers in cancer patients with congestive heart failure leads to severe adverse cardiovascular effects. Circulation. 2003;109(suppl 4):665
  64. Iliescu C, Yusuf SW, Swafford J, et al. Impact of angiotensin converting enzyme inhibitors and carvedilol on recovery of cardiac function in Imatinib (gleevac) associated cardiomyopathy. J Card Fail. 2005;11(suppl):54
  65. Shaik N, Yusuf SW, Swafford J, et al. The role of Valsartan and Carvedilol in patients with chemotherapy associated cardiomyopathy who are intolerant to angiotensin converting enzyme inhibitors. J Card Fail. 2005;(Suppl 11):87
  66. Woods ML, Yusuf SW, Swafford J, et al. Milrinone and Carvedilol in medical management of chemotherapy induced acute decompensated class 1V heart failure. J Cardiac Fail. 2002;8(suppl):296
  67. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89:942–949
  68. Ganame J, Claus P, Eyskens B, et al. Acute cardiac functional and morphological changes after Anthracycline infusions in children. Am J Cardiol. 2007;99:974–977
  69. Zeidman A, Dicker D, Mittelman M. Interferon-induced vasospasm in chronic myeloid leukaemia. Acta Haematol. 1998;100:94–96
  70. Lu JI, Carhart RL, Graziano SL, et al. Acute coronary syndrome secondary to fluorouracil infusion. J Clin Oncol. 2006;24:2959–2960
  71. Frickhofen N, Beck FJ, Jung B, et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002;13:797–801
  72. Cardinale D, Colombo A, Colombo N. Acute coronary syndrome induced by oral capecitabine. Can J Cardiol. 2006;22:251–253
  73. Schrader C, Keussen C, Bewig B, et al. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res. 2005;10:498–501
  74. Stefenelli T, Kuzmits R, Ulrich W, et al. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9:552–556
  75. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106
  76. Rutqvist LE, Johansson H. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer. 1990;61:866–868
  77. Paszat LF, Mackillop WJ, Groome PA, et al. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol. 1998;16:2625–2631
  78. Giordano SH, Kuo YF, Freeman JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97:419–424
  79. Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet. 2000;355:1757–1770
  80. Harris JR, Hellman S. Put the “hockey stick” on ice. Int J Radiat Oncol Biol Phys. 1988;15:497–499
  81. Vallis KA, Pintilie M, Chong N, et al. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol. 2002;20:1036–1042
  82. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270:1949–1955
  83. Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med Phys. 2002;29:2391–2403
  84. Jurado J, Thompson PD. Prevention of coronary artery disease in cancer patients. Pediatr Blood Cancer. 2005;44:620–624
  85. Stewart JR, Fajardo LF. Radiation-induced heart disease: an update. Prog Cardiovasc Dis. 1984;27:173–194
  86. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol. 1996;27:766–773
  87. Brosius FC, Waller BF, Roberts WC. Radiation heart disease (Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart). Am J Med. 1981;70:519–530
  88. McEniery PT, Dorosti K, Schiavone WA, et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol. 1987;60:1020–1024
  89. Stewart JR, Fajardo LF, Gillette SM, et al. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31:1205–1211
  90. Theodoulou M, Seidman AD. Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol. 2003;30:730–739
  91. Tribble DL, Barcellos-Hoff MH, Chu BM, et al. Ionizing radiation accelerates aortic lesion formation in fat-fed mice via SOD-inhibitable processes. Arterioscler Thromb Vasc Biol. 1999;19:1387–1392
  92. Sarkiss MG, Yusuf SW, Warneke CL, et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer. 2007;109:621–627
  93. Orzan F, Brusca A, Conte MR, et al. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J. 1993;69:496–500
  94. Katz NM, Hall AW, Cerqueira MD. Radiation induced valvulitis with late leaflet rupture. Heart. 2001;86:E20
  95. Rituxan package insert. San Diego, CA: IDEC Pharmaceuticals; 2001;
  96. Cersosimo RJ. Monoclonal antibodies in the treatment of cancer (Part 1). Am J Health Syst Pharm. 2003;60:1531–1548
  97. Herceptin package insert. San Francisco: Genentech; 2001;
  98. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  99. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results froma large observational registry in the US (BRiTE). J Clin Oncol. 2006;24(suppl):155s;(abstract 3536)
  100. Trousseau A. Phlegmasia Alba dolens (Clinique Medicale de l’Hotel-Dieu de Paris). In: London: The New Sydenham Society; 1865;p. 94–99
  101. Khorana AA. Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost. 2003;1:2463–2465
  102. Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol. 1990;17:147–159
  103. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404–407
  104. Goodnough LT, Saito H, Manni A, et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen (A study of 159 patients). Cancer. 1984;54:1264–1268
  105. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886–889
  106. Nordstrom M, Lindblad B, Anderson H, et al. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ. 1994;308:891–894
  107. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3:27–34
  108. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–815
  109. Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104:2822–2829
  110. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296:2558–2560
  111. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614–1615
  112. Urbauer E, Kaufmann H, Nosslinger T, et al. Thromboembolic events during treatment with thalidomide. Blood. 2002;99:4247–4248
  113. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–1030
  114. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol. 2005;23:2574–2576
  115. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65
  116. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006;24:3354–3360
  117. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol. 2003;21:3542–3543
  118. Sevelda P, Mayerhofer K, Obermair A, et al. Thrombosis with paclitaxel. Lancet. 1994;343:727
  119. Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18:2169–2178
  120. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005;23:9130–9137
  121. Behrendt CE, Ruiz RB. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost. 2003;90:734–737
  122. Recio FO, Piver MS, Hempling RE, et al. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer. 1996;78:2157–2163
  123. Licciardello JT, Moake JL, Rudy CK, et al. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology. 1985;42:296–300
  124. Pretnar-Oblak J, Zaletel M, Jagodic M, et al. Thrombosis of internal carotid artery after cisplatin-based chemotherapy. Eur Neurol. 2007;57:109–110
  125. Kearon C, Julian JA, Newman TE, et al. Noninvasive diagnosis of deep venous thrombosis (McMaster Diagnostic Imaging Practice Guidelines Initiative). Ann Intern Med. 1998;128:663–677Erratum in: Ann Intern Med 1998;129:425
  126. Bates SM, Ginsberg JS. Clinical practice (Treatment of deep-vein thrombosis). N Engl J Med. 2004;351:268–277
  127. Torbicki A, Van Beek EJR, Charbonnier B, et al. Task Force on Pulmonary Embolism (European Society of Cardiology Guidelines on diagnosis and management of acute pulmonary embolism). Eur Heart J. 2000;21:1301–1336
  128. Yusuf SW, Woods M, Swafford J. Medical image (Pulmonary grume). NZ Med J. 2006;119:U2126
  129. Kaplan BM, Miller AJ, Bharati S, et al. Complete AV block following mediastinal radiation therapy: electrocardiographic and pathologic correlation and review of the world literature. J Interv Card Electrophysiol. 1997;1:175–188
  130. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141–157
  131. Takenaka S, Mitsudo K, Inoue K, et al. Successful treatment of primary cardiac lymphoma with atrioventricular nodal block. Int Heart J. 2005;46:927–931
  132. Okmen E, Erdinler I, Oguz E, et al. An unusual cause of reflex cardiovascular syncope: vagal paraganglioma. Ann Noninvasive Electrocardiol. 2003;8:173–176
  133. Owen PJ, Lazarus JH, Morse RE. Unusual complications of thyroid carcinoma. Postgrad Med J. 2003;79:55–56
  134. Altundag O, Celik I, Kars A. Recurrent asymptomatic bradycardia episodes after cisplatin infusion. Ann Pharmacother. 2001;35:641–642
  135. Miya T, Fujikawa R, Fukushima J, et al. Bradycardia induced by irinotecan: a case report. Jpn J Clin Oncol. 1998;28:709–711
  136. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111:273–279
  137. Lai KH, Tsai YT, Lee SD, et al. Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemother Pharmacol. 1989;23:54–56
  138. Dilger JA, Rho EH, Que FG, et al. Octreotide-induced bradycardia and heart block during surgical resection of a carcinoid tumor. Anesth Analg. 2004;98:318–320table of contents
  139. Hinterseer M, Becker A, Kaab S, et al. Thalidomide-induced symptomatic third-degree atrioventricular block. Clin Res Cardiol. 2006;95:474–476
  140. Perez-Verdia A, Angulo F, Hardwicke FL, et al. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy. 2005;25:1271–1276
  141. Huang CH, Chen WJ, Wu CC, et al. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient. Pacing Clin Electrophysiol. 1999;22:965–967
  142. Ferlitsch A, Kreil A, Bauer E, et al. Bradycardia and sinus arrest during percutaneous ethanol injection therapy for hepatocellular carcinoma. Eur J Clin Invest. 2004;34:218–223
  143. Kilickap S, Akgul E, Aksoy S, et al. Doxorubicin-induced second degree and complete atrioventricular block. Europace. 2005;7:227–230
  144. Franchin G, Vaccher E, Gobitti C, et al. Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma. Oral Oncol. 2005;41:526–533
  145. Satoh K, Sakamoto N, Shinohe Y, et al. Indigo carmine-induced bradycardia in a patient during general anesthesia. Anesth Analg. 2001;92:276–277
  146. Keefe DL. The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?. Oncologist. 2002;7:65–72
  147. Schurmeyer TH, Engeroff B, Dralle H, et al. Cardiological effects of catecholamine-secreting tumours. Eur J Clin Invest. 1997;27:189–195
  148. Paschalis-Purtak K, Pucilowska B, Prejbisz A, et al. Cardiac arrests, atrioventricular block, and pheochromocytoma. Am J Hypertens. 2004;17:544–545
  149. Engelen MA, Juergens KU, Breithardt G, et al. Interatrial conduction delay and atrioventricular block due to primary cardiac lymphoma. J Cardiovasc Electrophysiol. 2005;169:26
  150. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Am Coll Cardiol. 2002;40:1703–1719
  151. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354:1625–1633
  152. Dessertenne F. Ventricular tachycardia with two variable opposing foci. Arch Mal Coeur Vaiss. 1966;59:263–272
  153. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 1983;2:806–817
  154. Walker G, Wilcock A, Carey AM, et al. Prolongation of the QT interval in palliative care patients. J Pain Symptom Manage. 2003;26:855–859
  155. Soignet SL. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist. 2001;6(suppl 2):11–16
  156. www.torsades.orgaccessed on May 4, 2007
  157. Ferrari S, Figus E, Cagnano R, et al. The role of corrected QT interval in the cardiologic follow-up of young patients treated with Adriamycin. J Chemother. 1996;8:232–236
  158. Oztop I, Gencer M, Okan T, et al. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level (QT interval and dispersion in patients with gastrointestinal system cancers). Jpn J Clin Oncol. 2004;34:262–268
  159. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res. 2004;10:96–100
  160. Saliba W, Erdogan O, Niebauer M. Polymorphic ventricular tachycardia in a woman taking cesium chloride. Pacing Clin Electrophysiol. 2001;24:515–517
  161. Gowda RM, Khan IA, Wilbur SL, et al. Torsade de pointes: the clinical considerations. Int J Cardiol. 2004;96:1–6
  162. Committee for Propierary Medicinal Products. Points to consider; The assessment of the potential for QT interval prolongation by non cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products. London 17th. http://www.eudra.org/emea.htmlaccessed on May 4 2007
  163. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866–1874
  164. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–1022
  165. Zeltser D, Justo D, Halkin A. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003;82:282–290
  166. Murray KT. Ibutilide. Circulation. 1998;97:493–497
  167. Abernethy DR, Flockhart DA. Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. Circulation. 2000;101:1749–1753
  168. TRISENOX. www.fda.gov
  169. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77:392–397
  170. Assimes TL, Malcolm I. Torsade de pointes with sotalol overdose treated successfully with lidocaine. Can J Cardiol. 1998;14:753–756
  171. Vukmir RB, Stein KL. Torsades de pointes therapy with phenytoin. Ann Emerg Med. 1991;20:198–200
  172. Kocheril AG, Bokhari SA, Batsford WP. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol. 1997;20:2810–2816

 The authors have no conflicts of interest to disclose.

PII: S0146-2806(08)00004-2

doi: 10.1016/j.cpcardiol.2008.01.002

Current Problems in Cardiology
Volume 33, Issue 4 , Pages 163-196 , April 2008

Article Tools

* Image Usage & Resolution